Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’’ by Zouet al

We thank Zou and colleagues for their interests insightful comments1 on our recently published work2 are impressed by the encouraging results of tofacitinib patients with refractory Behcet’s uveitis (BU). In this study, 5 mg two times per day was given to active BU prednisone reduced from 50 60 30 withdrawal conventional immunosuppressants (cyclosporine A or tacrolimus), which lead treatment ‘success’ ‘flare’ in 10 (76.9%) 3 (23.1%) 13 included patients, respectively. Moreover, all responded …